Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Palomar Medical Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ted Molczan who wrote (659)	5/24/1998 12:50:00 AM
From: Dave Peterson	Respond to of 708

Thanks Ted, Your in depth analysis confirms the pessimistic outlook I have toward the company. I don't think the value of my shares is worth much more than the commission on the trade. Sounds like lasers aren't going to surpass tweezers in the near future - for Palomar anyway. To summarize: Poor margin; excess COG, RD, and marketing costs; diminishing demand for the product; and too many shares outstanding. Out standing in the rain. dp

To: Ted Molczan who wrote (659)	5/26/1998 2:23:00 AM
From: David Wise	Read Replies (1) \| Respond to of 708

Ted, I sure would like to know what your interest in ripping PMTI is. For at least the past year you've had many posts, obviously time consuming, and always negative. Surely you don't like this stock as a short at this price. Were you ever long? Also, you're very mistaken about the MEHL lawsuit. You say that winning this will not affect their sales. You forget that MEHL used illegal scare tactics against prospective and current customers, threatening to sue PMTI customers if they used the product. Now that PMTI can show that MEHL is out of the game, it could have a very big effect. Maybe that's why you're always writing against PMTI - you hold stock in MEHL which has now been de-listed from NASDAQ and may go bankrupt. Or is it another competitor? PMTI's biggest mistakes were 1) thinking they'd get FDA approval faster than they did, and 2) stretching their R & D dollars too thin - investing in many development stage companies that may be profitable some day, but which ate up funds, requiring that constant additional funds be raised. They've divested themselves of most of these and have good potential for profit. How much is a valid question, but I feel very safe in concluding they will be profitable soon. PMTI's stock slump started with MEHL's suit right after they finally got FDA approval. I expect, after mild ups and downs, PMTI's reversal is about to start. I'm not saying they'll get back to $10 this quarter, but they are finally back on the right track. Now if they can can stop issuing stock and grow from cash flow, maybe they can even reduce shares outstanding.